Tetraphase Pharmaceuticals Inc (TTPH.OQ)
TTPH.OQ on NASDAQ Stock Exchange Global Select Market
3.19USD
20 Apr 2018
3.19USD
20 Apr 2018
Change (% chg)
$0.05 (+1.59%)
$0.05 (+1.59%)
Prev Close
$3.14
$3.14
Open
$3.13
$3.13
Day's High
$3.26
$3.26
Day's Low
$3.12
$3.12
Volume
100,655
100,655
Avg. Vol
311,363
311,363
52-wk High
$8.75
$8.75
52-wk Low
$2.06
$2.06
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 2.53 | -0.456 |
| Sep '17 | 4.07 | -0.634 | |
| Jun '17 | 1.59 | -0.831 | |
| Mar '17 | 1.49 | -0.794 | |
| FY 2016 | Dec '16 | 1.09 | -0.609 |
| Sep '16 | 0.85 | -0.575 | |
| Jun '16 | 1.24 | -0.469 | |
| Mar '16 | 1.96 | -0.457 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5 | 1.77 | 2.17 | 1.30 | -- |
| Quarter Ending Sep-18 | 5 | 1.35 | 1.80 | 0.90 | -- |
| Year Ending Dec-18 | 7 | 7.84 | 12.31 | 5.00 | 6.50 |
| Year Ending Dec-19 | 7 | 23.34 | 46.03 | 8.70 | 18.19 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 5 | -0.39 | -0.29 | -0.50 | -- |
| Quarter Ending Sep-18 | 5 | -0.41 | -0.30 | -0.54 | -- |
| Year Ending Dec-18 | 7 | -1.64 | -1.21 | -1.96 | -2.37 |
| Year Ending Dec-19 | 7 | -1.28 | -0.96 | -1.82 | -1.80 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.95 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 40.70 | 45.72 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.22 | |
| Beta | 2.59 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 79.06 | 3.94 | 5.71 | |
| Price to Book (MRQ) | 2.90 | 4.80 | 5.37 | |
| Price to Tangible Book (MRQ) | 3.70 | 5.61 | 6.95 | |
| Price to Cash Flow (TTM) | -- | 22.91 | 23.32 | |
| % Owned Institutions | 46.51 | 1.21 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
| Payout Ratio(TTM) | -- | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 27.59 | 3.69 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -41.27 | 4.83 | 5.69 | |
| Sales - 5 Yr. Growth Rate | 94.47 | 10.08 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -77.33 | 16.36 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -46.60 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.87 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | 43.32 | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.12 | 2.19 |
| Current Ratio (MRQ) | 6.12 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 9.88 | 12.18 |
| Total Debt to Equity (MRQ) | 0.00 | 13.86 | 16.45 |
| Interest Coverage (TTM) | -371.75 | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 54.81 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.15 | 52.20 | |
| EBITD Margin (TTM) | -2,095.27 | -- | -- | |
| EBITD - 5 Yr. Avg | -608.22 | 18.57 | 10.96 | |
| Operating Margin (TTM) | -2,102.20 | 14.36 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -610.67 | 14.52 | 6.40 | |
| Pre-Tax Margin (TTM) | -2,092.20 | 14.82 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -618.28 | 14.90 | 6.81 | |
| Net Profit Margin (TTM) | -2,092.20 | 11.08 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -618.28 | 11.20 | 3.09 | |
| Effective Tax Rate (TTM) | -- | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.42 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 75,924 | 938,079,949 | 846,830,978 | |
| Net Income/Employee (TTM) | -1,588,485 | 110,368,367 | 99,616,195 | |
| Receivable Turnover (TTM) | 1.77 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 0.03 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -66.47 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -49.48 | 12.91 | 12.31 | |
| Return on Investment (TTM) | -73.69 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -55.43 | 16.88 | 16.10 | |
| Return on Equity (TTM) | -73.76 | 16.34 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -77.07 | 17.98 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -55.97 | -21.13 | 94.47 |
| EPS (TTM) % | 10.52 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Tetraphase Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 12.79 | 8.90 | 99 | 23 |
| 13 Week | 8.08 | 2.81 | 99 | 34 |
| 26 Week | -6.62 | -13.72 | 99 | 29 |
| 52 Week | 105.29 | 74.00 | 99 | 12 |
| YTD | 92.56 | 69.10 | 99 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Tetraphase Pharma Q4 Loss Per Share $0.46
- BRIEF-Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline
- BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines
- Tetraphase's antibiotic fails late-stage study, shares plummet
- BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI
Institutional Holders
| % Shares Owned: | 60.80% |
| # of Holders: | 144 |
| Total Shares Held: | 31,390,257 |
| 3 Mo. Net Change: | -894,126 |
| # New Positions: | 5 |
| # Closed Positions: | 3 |
| # Increased Positions: | 11 |
| # Reduced Positions: | 7 |
| # Net Buyers: | 4 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.